ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

GNVC Genvec, Inc.

7.193
0.00 (0.00%)
Apr 25 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0
Bid Price 0.35
Ask Price 7.19
News -
Share Name Share Symbol Market Stock Type
Genvec, Inc. GNVC NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.00 0.00% 7.193 19:00:00
Open Price Low Price High Price Close Price Previous Close
7.193 7.193
Trades Shares Traded Average Volume
0 0 -
Last Trade Type Quantity Price Currency
- 0 US$ 7.193 USD

Genvec, Inc. Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
US$ 7.60M - - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Genvec, Inc. News

Real-Time news about Genvec, Inc. (NASDAQ): 0 recent articles
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No GNVC Message Board. Create One! See More Posts on GNVC Message Board See More Message Board Posts

Historical GNVC Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.000.000.000.0000.000.00%
1 Year0.000.000.000.0000.000.00%
3 Years0.000.000.000.0000.000.00%
5 Years0.000.000.000.0000.000.00%

Genvec, Inc. Description

Genvec Inc was incorporated under the laws of the state of Delaware on December 7, 1992.The Company is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. Its development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus or RSV, herpes simplex virus or HSV, and malaria. In the area of animal health the Company is developing vaccines against foot-and-mouth disease or FMD. In collaboration with Novartis, the Companys hearing and balance disorders program is focused on the restoration of hearing and balance function through the regeneration of critical cells of the inner ear.

Your Recent History

Delayed Upgrade Clock